Sareum (SAR), together with its US-based licensee Sierra Oncology, should be a major beneficiary in competitive terms from an apparent decision by Lilly to discontinue development its Chk1 inhibitor, prexasertib. Sierra has the only other compound with this mechanism in clincial trials and, as a result, its Chk1 inihitibitor, SRA737 – which originated at Sareum […]
Warning: array_map(): Expected parameter 2 to be an array, null given in
/homepages/46/d771497103/htdocs/winter/wp-content/themes/quoteddata/inc/theme-functions.php on line
124
Warning: count(): Parameter must be an array or an object that implements Countable in
/homepages/46/d771497103/htdocs/winter/wp-content/themes/quoteddata/inc/theme-functions.php on line
125